Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Cash Flow (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Net Cash Flow for 11 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 109.28% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.9 million, a 178.11% increase, with the full-year FY2025 number at $45.9 million, up 178.11% from a year prior.
  • Net Cash Flow was $4.4 million for Q4 2025 at Iovance Biotherapeutics, down from $26.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $311.8 million in Q1 2023 to a low of -$249.7 million in Q2 2023.
  • A 3-year average of -$5.6 million and a median of -$17.9 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 265.78% in 2024, then skyrocketed 237.98% in 2025.
  • Iovance Biotherapeutics' Net Cash Flow stood at -$155.9 million in 2023, then soared by 69.64% to -$47.3 million in 2024, then soared by 109.28% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Net Cash Flow are $4.4 million (Q4 2025), $26.4 million (Q3 2025), and -$40.4 million (Q2 2025).